Navigation Links
New Study in Journal of Pediatrics Suggests Synagis (Palivizumab),May Reduce Subsequent Recurrent Wheezing in Preterm Infants

ollowed by a healthy period of at least one week. The study also evaluated the incidence of physician-diagnosed recurrent wheezing, defined as three or more episodes of wheezing in the prior 12 months, as verified by a physician at a physician's office, emergency room or hospital.

Clinical Trial Results

After following these infants for two years, the results showed the following key findings:

The incidence of recurrent wheezing was 49 percent lower among children who received Synagis compared to those who did not (13 percent vs. 26 percent, p=0.001). There was also significantly less physician-diagnosed recurrent wheezing in the group that received Synagis (8 percent vs. 16 percent, p=0.011).

In addition, infants who received Synagis had a significantly longer time to onset of both recurrent wheezing and physician-diagnosed recurrent wheezing, compared with the combined non-prophylaxed group.

About Synagis

Synagis is the only monoclonal antibody approved by the U.S. Food and Drug Administration (FDA) to help prevent an infectious disease. Synagis is indicated for the prevention of serious lower respiratory tract disease caused by RSV in children at high risk of RSV disease.

Synagis was approved for use in the United States in 1998, Europe in 1999, and Japan in 2002. Synagis is currently available in 62 countries.

The safety and efficacy of Synagis were established in infants with bronchopulmonary dysplasia, infants with a history of prematurity (less than or equal to 35 weeks gestational age), and children with hemodynamically significant congenital heart disease. The first dose of Synagis should be administered prior to commencement of the RSV season, which usually starts in the fall and runs through the spring. Patients, including those who develop an RSV infection, should continue to receive monthly doses throughout the season.

Abbott has exclusive rights to Synagis in markets outside the United Stat
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:9/19/2014)... , Sept. 19, 2014 Intarcia ... interim clinical data for its lead candidate ITCA 650 ... patients with high baseline HbA1c levels at the 50 ... the Study of Diabetes (EASD). Data from the open-label, ... levels of blood sugar in patients with poorly controlled ...
(Date:9/18/2014)... DUBLIN , September 19, 2014 /PRNewswire/ ... and Markets ( http://www.researchandmarkets.com/research/qqjrnh/global_molecular ) has announced ... Cytogenetics Market 2014-2018" report to their ... ,Molecular Cytogenetics involves the study of chromosomes ... and functions of genes and chromosomes. It ...
(Date:9/18/2014)...  PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results ... June 30, 2014. Quarter Ended June ... 30, 2014 increased $492,000, or 18%, to $3.2 million ... 30, 2013, due primarily to an increase of $746,000 ... Company,s largest customer, partially offset by an aggregate decrease ...
Breaking Medicine Technology:Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 2Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 3Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 2Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 3Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 4Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 5Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 6Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 7Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 8Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 9Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 10Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 11Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 12Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 13
... May 7, 2012 A new analysis concludes that rituximab, ... treatment responses lasting at least five years in approximately one ... of bleeding due to chronic immune thrombocytopenic purpura (ITP). In ... Blood , the Journal of the American Society ...
... Mass., May 7, 2012  CardioFocus, Inc., developer of ... treatment of atrial fibrillation (AF), announces that its ... the scientific sessions and during a private academic ... Society,s 33rd Annual Scientific Sessions, May 9-12 in ...
Cached Medicine Technology:Rituximab Promotes Long-Term Response for Patients with Immune Destruction of Platelets 2Rituximab Promotes Long-Term Response for Patients with Immune Destruction of Platelets 3Worldwide Multicenter Experiences with CardioFocus HeartLight® EAS to be Presented at Heart Rhythm 2012 2Worldwide Multicenter Experiences with CardioFocus HeartLight® EAS to be Presented at Heart Rhythm 2012 3
(Date:9/19/2014)... September 19, 2014 -- Recent two-generation approaches to ... are receiving increasing attention from researchers, advocates, and ... to enable them to move to jobs that ... early care and education for children, these programs ... However, according to a new report from ...
(Date:9/19/2014)... As summer vacations end and everyone returns ... now reminds area patients about the reality and impact of ... affected by gum disease, there is simply not an option ... years Dr. Krishnan has treated patients with varying degrees of ... that come in due to common symptoms such as bleeding ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 Recently, ... and announced that JustHost, IX Web Hosting and ... , “As is known to most people, ... partitioning a physical server computer into many servers, ... of running on someone’s own dedicated computer,” the ...
(Date:9/19/2014)... are notoriously difficult to study with X-ray crystallography, not ... impossible, to crystallize, but also because their very nature ... when a structure can be obtained it is often ... of protein domains that sometimes create more puzzles than ... Cryst . D70, 2241-2255; doi: 10.1107/S1399004714016496 ] , ...
(Date:9/19/2014)... 2014 Top10BestSEOHosting.com today compares many ... HostMonster, Arvixe and Bluehost are the best suppliers ... quality WordPress hosting (including VPS and cloud hosting) ... more detailed information. , HostMonster ( http://www.hostmonster.com/track/seohosts ) ... at a fraction of the cost. As a ...
Breaking Medicine News(10 mins):Health News:A two generation lens: Current state policies fail to support families with young children 2Health News:New York Periodontist Dr. Prabha Krishnan Now Raises Awareness about the Dangers of Untreated Decay, Gingivitis and Gum Disease During Self-Awareness Month 2Health News:New York Periodontist Dr. Prabha Krishnan Now Raises Awareness about the Dangers of Untreated Decay, Gingivitis and Gum Disease During Self-Awareness Month 3Health News:Top10BestSEOHosting.com: JustHost is One of the Best VPS Suppliers in 2014 2Health News:A refined approach to proteins at low resolution 2Health News:A refined approach to proteins at low resolution 3Health News:Top10BestSEOHosting.com: They Are Best Windows Web Hosting Suppliers Of 2014 2
... The international team of researchers from the United States and ... both assassin and messenger. This led to the // race ... cell. Cells that could seek out and destroy cancer have ... the Seraph Professor of Oncology at the Johns Hopkins Kimmel ...
... College of Georgia said that genes that control blood pressure ... on more than 500 pairs of black and // white ... that changes in gene expression between ages 14 and 18 ... variation that occurred by age 18. The results were presented ...
... in matters of sleep till late the reason being ... ray of new light comes the IST project 'Sensation' ... different // countries, addressing sensing of physiological parameters, core ... a multipurpose sensing platform consisting of 17 micro sensors ...
... in Mumbai were crippled as the striking doctors were determined ... dry. All the government hospitals in Mumbai suffered due to ... from 15 government-managed hospitals in this bustling city of over ... 27, demanding better security while on the job after relatives ...
... A research has found out that a sudden emotional stress ... beloved ones or failure// in romance are said to be ... ,Researchers at Johns Hopkins University found that shock could ... attack causing severe heart muscle weakness, reported health portal Health ...
... Center researchers have discovered that distinct regions of the ... ambiguous choices versus// choices involving only risk. The investigators ... and how such risk-taking can become an addition or ... in the journal Neuron. ,The research was ...
Cached Medicine News:Health News:Two in One Cell Offers Hope to Find a Cure for Cancer 2Health News:Genetic Reasons behind Change in One’s Blood Pressur 2Health News:Sleep Science awakens from deep slumber! 2Health News:Health Services Came To A Halt As Mumbai Doctors Strike Continues 2Health News:Distinct Brain Sections Are Activated While Making Risky Decisions 2
... has been selling replacement bulbs ... and we are extremely proud ... Check out our catalog of ... discount light bulbs specials. ...
... Bulb Direct has been ... Internet since 1996, and we ... 100% satisfaction guarantee. Check out ... and see our discount light ...
... has been selling replacement bulbs ... and we are extremely proud ... Check out our catalog of ... discount light bulbs specials. ...
... been selling replacement bulbs on ... we are extremely proud of ... out our catalog of replacement ... light bulbs specials. ,Check ...
Medicine Products: